The strength of our Group, which is unique in the country, lies in the willingness of participating public institutions to pool their strengths, expertise and experiences with respect to best practices based on Research that cares.
It is this common willingness, combined with the support of several leading partners, that allows us to launch innovative initiatives with and for people with breast cancer.
Our initiatives emerge from the priorities established by the members of our Board of Directors and our Scientific Committee, who are experts in their respective fields.
Here are some of our initiatives to increase awareness and participation of breast cancer patients in clinical trials:
Supported by a $2.5 million donation over 5 years from Breast Cancer Canada, the main objectives of the McPeak-Sirois Group’s Programme Accès-recherche Dr. André-Robidoux are to increase:
The addition of hospitals to the consortium helps to create a multi-institutional network. This allows the Group to obtain more research protocols and fosters attractiveness to pharmaceutical companies and other groups that fund these studies.
A win-win situation that ultimately benefits patients, as Kimberly Carson, CEO of Breast Cancer Canada, points out:
“Together, we are expanding access to clinical trials and reaching more Canadian breast cancer patients. This partnership represents a significant step forward in our ongoing mission to improve outcomes and transform the breast cancer landscape, so it is personalized to each individual.”
“This funding will lead to substantial growth for our consortium, enabling the expansion of clinical trial offerings across the province of Quebec. As a former patient and clinical trial participant myself, I know how important it is to be given access to research that cares, regardless of where you live.” says Susan McPeak, co-founder of the McPeak-Sirois Group.
The Programme Accès Recherche Dr. André-Robidoux was launched in 2016 by the Group and funded from 2017 to 2022 thanks to a $1.4 million donation from the Quebec Breast Cancer Foundation. During this period, six hospitals joined our Group.
Initiated by its Scientific Committee, and under the leadership of Dr. Sarkis Meterissian, the McPeak-Sirois Group set up the first Quebec Metastatic Breast Cancer Registry, which benefits from the full support of the Ministère de la Santé et des Services sociaux (MSSS) as well as of the Direction nationale du Programme québécois de cancérologie.
Launched in 2021 with the financial support of four pharmaceutical companies and the Quebec Breast Cancer Foundation, the Registry is gradually being extended to the other member hospitals of the consortium, thanks to the support of the Canadian Cancer Society, which has become the lead sponsor, and the continued support of pharmaceutical companies.
With this group, Mr. Sirois and Mrs. McPeak have accomplished the unthinkable: bringing together hospitals that were previously competitors.
Late Dr. André Robidoux, Oncologist at CHUM and founding president of the scientific committee.
Improving the fight against breast cancer by increasing access to and participation in clinical research studies.
In order to make the text more readable, patients is used in the feminine form since breast cancer mainly affects women.
Website conception and design | Cobbox